Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Eli Lilly weight-loss drug 'significantly' reduces sleep apnoea

(Sharecast News) - Eli Lily's weight-loss drug tirzepatide has been shown to "significantly" reduce sleep apnoea severity, the US drugs giant said on Wednesday. The firm said phase 3 clinical trials had showed that tirzepatide - which is sold as Zepbound in the US - "significantly reduced the apnoea-hypopnea index (AHI) compared to a placebo, achieving the primary endpoints".

In particular, it achieved a mean AHI reduction of up to 63%, or about 30 fewer events per hour.

It was also shown to improve symptoms in those with moderate-to-severe obstructive sleep apnoea (OSA) and obesity with and without positive airway pressure therapy.

Eli Lilly said it would now submit the data for global regulatory review.

Jeff Emmick, senior vice president, product development, at Eli Lilly, said: "OSA impacts 80m adults in the US, with more than 20m living with moderate-to-severe OSA. However, 85% of cases go undiagnosed and therefore untreated.

"Addressing this unmet ned head-on is critical, and while there are pharmaceutical treatments for the excessive sleepiness associated with OSA, tirzepatide has to the potential to be the first pharmaceutical treatment for the underlying disease."

Weight-loss drugs such as Zepbound and Novo Nordisk's Wegovy, known as GLP-1 agonists, were designed to treat obesity and diabetes, and already generated billions of dollars of sales since coming to market.

However, evidence increasingly appears to suggest they can treat other diseases as well, such as OSA. Last month, Wegovy was approved by the US Food and Drug Administration a treatment for lowering strong and heart attack risk in obese adults.

As at 1330 BST, Eli Lily had put on 2% in pre-market trading.

OSA is a sleep-related breathing disorder that is characterised by the partial or complete collapse of the upper airway during sleep.

Share this article

Related Sharecast Articles

Hummingbird announces restart at Kouroussa
(Sharecast News) - Hummingbird Resources announced the remobilization of Corica Mining Services at the Kouroussa Gold Mine in Guinea on Friday, after a work stoppage on March 17.
Drilling to start on Oracle's Northern Zone project
(Sharecast News) - Oracle Power announced on Friday that drilling is set to start next week at the Northern Zone Gold Project, 25 kilometres east of Kalgoorlie in Western Australia.
Fulcrum Metals extends date for sale of uranium assets
(Sharecast News) - Fulcrum Metals announced an extension to the completion date for the proposed sale of its Saskatchewan uranium projects to Terra Balcanica Resources on Friday.
PipeHawk subsidiary awarded £0.75m contract
(Sharecast News) - PipeHawk announced on Friday that an unnamed building materials company had awarded its subsidiary QM Systems a significant contract.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.